Vericel Co. (NASDAQ:VCEL - Free Report ) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Vericel in a research report issued to clients and investors on Thursday, May 9th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of $0.04 for the quarter. HC Wainwright has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Vericel's current full-year earnings is $0.09 per share. HC Wainwright also issued estimates for Vericel's Q2 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.30 EPS.
Get Vericel alerts:
Sign Up
Other equities analysts also recently issued research reports about the company. Truist Financial reissued a "buy" rating and set a $54.00 target price on shares of Vericel in a research report on Tuesday, March 26th. TheStreet raised shares of Vericel from a "d+" rating to a "c-" rating in a research note on Monday, January 29th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $46.80.
Read Our Latest Stock Analysis on VCEL
Vericel Stock Down 1.1 % NASDAQ VCEL traded down $0.55 during trading hours on Friday, hitting $48.10. 315,714 shares of the company were exchanged, compared to its average volume of 523,110. The stock has a market cap of $2.33 billion, a PE ratio of -534.44 and a beta of 1.74. Vericel has a 52 week low of $30.18 and a 52 week high of $53.05. The stock has a 50-day moving average price of $47.37 and a 200 day moving average price of $41.76.
Vericel (NASDAQ:VCEL - Get Free Report ) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $51.28 million for the quarter, compared to analysts' expectations of $49.07 million. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The business's revenue was up 25.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share.
Insider Activity In related news, SVP Sean C. Flynn sold 8,115 shares of the business's stock in a transaction on Friday, March 8th. The stock was sold at an average price of $45.33, for a total transaction of $367,852.95. Following the transaction, the senior vice president now directly owns 167 shares in the company, valued at approximately $7,570.11. The sale was disclosed in a document filed with the SEC, which can be accessed through this link . In other news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $44.67, for a total value of $781,725.00. Following the sale, the chief executive officer now owns 194,870 shares in the company, valued at $8,704,842.90. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website . Also, SVP Sean C. Flynn sold 8,115 shares of the company's stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $45.33, for a total transaction of $367,852.95. Following the transaction, the senior vice president now owns 167 shares of the company's stock, valued at approximately $7,570.11. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 54,267 shares of company stock worth $2,450,996. Corporate insiders own 7.20% of the company's stock.
Hedge Funds Weigh In On Vericel Hedge funds and other institutional investors have recently made changes to their positions in the company. MCF Advisors LLC raised its stake in Vericel by 86.1% in the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 223 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Vericel in the first quarter worth about $27,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Vericel in the fourth quarter worth about $33,000. GAMMA Investing LLC acquired a new position in Vericel during the fourth quarter worth about $65,000. Finally, RiverPark Advisors LLC acquired a new stake in Vericel in the 1st quarter valued at about $147,000.
Vericel Company Profile (
Get Free Report )
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Recommended Stories
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
